Farallon Capital Management LLC bought a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,000,981 shares of the company's stock, valued at approximately $13,914,000. Farallon Capital Management LLC owned approximately 1.98% of Tyra Biosciences at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Rhumbline Advisers lifted its stake in Tyra Biosciences by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock worth $364,000 after purchasing an additional 1,027 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Tyra Biosciences in the 4th quarter worth approximately $31,000. Bank of New York Mellon Corp lifted its stake in Tyra Biosciences by 5.2% in the 4th quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company's stock worth $626,000 after purchasing an additional 2,221 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Tyra Biosciences by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock worth $132,000 after purchasing an additional 3,236 shares in the last quarter. Finally, US Bancorp DE purchased a new stake in Tyra Biosciences in the 4th quarter worth approximately $50,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
TYRA has been the topic of several research reports. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, March 31st. Wedbush restated an "outperform" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, March 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $30.83.
View Our Latest Analysis on Tyra Biosciences
Tyra Biosciences Price Performance
Tyra Biosciences stock traded down $0.52 during trading hours on Wednesday, reaching $9.46. The stock had a trading volume of 126,287 shares, compared to its average volume of 260,721. The stock has a market cap of $502.23 million, a PE ratio of -5.88 and a beta of 1.17. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60. The company has a fifty day simple moving average of $9.60 and a 200-day simple moving average of $13.00.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.
Tyra Biosciences Profile
(
Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Recommended Stories
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
